Inactive Instrument

Dna Group (T.R.) Ltd Stock TEL AVIV STOCK EXCHANGE

Equities

DNA

IL0011038523

Biotechnology & Medical Research

Sales 2022 0.56 2.11 Sales 2023 0.31 1.15 Capitalization 77.84M 293M
Net income 2022 -23M -86.68M Net income 2023 -1M -3.77M EV / Sales 2022 38,063,516 x
Net cash position 2022 65.73M 248M Net cash position 2023 66.7M 251M EV / Sales 2023 36,410,820 x
P/E ratio 2022
-3.6 x
P/E ratio 2023
-63.2 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 45.14%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 41 22-01-17
Director of Finance/CFO 43 15-11-14
Comptroller/Controller/Auditor 69 10-04-26
Members of the board TitleAgeSince
Director/Board Member 53 22-10-19
Chairman 50 21-02-23
Director/Board Member 48 19-03-18
More insiders
DNA Group TR Ltd, former DNA Biomedical Solutions Ltd, is an Israel-based company, which is engaged in the biotechnology sector. The Company's areas of activity include: the evaluation of bone density by measuring the velocity of the propagation of sound waves across the bone, using Bimmed, as well as the development of oral delivery of drugs, through its subsidiary, Entera Bio Ltd. Entera Bio Ltd focuses on the development of oral delivery of large molecules to address unmet medical needs. Entera Bio Ltd holds a patent, combining the following technologies: a synthetic molecule absorption enhancer, facilitating the absorption of large molecules and a proprietary formulation to prevent molecule degradation. Entera Bio Ltd’s proprietary oral delivery platform can be applied to a range of large molecules and biologicals. Entera Bio Ltd’s drugs are designated for the following medical conditions: Hypoparathyroidism and Osteoporosis.
More about the company